192 related articles for article (PubMed ID: 37791224)
1. Explosive Disease Progression After Single-Agent B-cell Maturation Antigen-Targeted Treatment in Multiple Myeloma: A Report of Three Cases in Sheikh Shakhbout Medical City.
Jaber W; Abdaljalil A; Ali A; Abu Haleeqa M; Mheidly K
Cureus; 2023 Aug; 15(8):e44433. PubMed ID: 37791224
[TBL] [Abstract][Full Text] [Related]
2. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
[TBL] [Abstract][Full Text] [Related]
3. Exposure-Response Analyses for Therapeutic Dose Selection of Belantamab Mafodotin in Patients With Relapsed/Refractory Multiple Myeloma.
Ferron-Brady G; Rathi C; Collins J; Struemper H; Opalinska J; Visser S; Jewell RC
Clin Pharmacol Ther; 2021 Nov; 110(5):1282-1292. PubMed ID: 34468979
[TBL] [Abstract][Full Text] [Related]
4. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
[TBL] [Abstract][Full Text] [Related]
5. Belantamab mafodotin for the treatment of multiple myeloma.
Wang B; Wu C; Zhong Q; Ling L; Wu Z; Yu B; Gao X; Zeng H; Yang DH
Drugs Today (Barc); 2021 Nov; 57(11):653-663. PubMed ID: 34821879
[TBL] [Abstract][Full Text] [Related]
6. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
Offidani M; Corvatta L; Morè S; Olivieri A
Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
[TBL] [Abstract][Full Text] [Related]
7. Longer term outcomes with single-agent belantamab mafodotin in patients with relapsed or refractory multiple myeloma: 13-month follow-up from the pivotal DREAMM-2 study.
Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Sborov D; Suvannasankha A; Weisel K; Voorhees PM; Womersley L; Baron J; Piontek T; Lewis E; Opalinska J; Gupta I; Cohen AD
Cancer; 2021 Nov; 127(22):4198-4212. PubMed ID: 34314018
[TBL] [Abstract][Full Text] [Related]
8. The role of belantamab mafodotin for patients with relapsed and/or refractory multiple myeloma.
Becnel MR; Lee HC
Ther Adv Hematol; 2020; 11():2040620720979813. PubMed ID: 33403093
[TBL] [Abstract][Full Text] [Related]
9. Single-agent belantamab mafodotin in patients with relapsed/refractory multiple myeloma: Final analysis of the DREAMM-2 trial.
Nooka AK; Cohen AD; Lee HC; Badros A; Suvannasankha A; Callander N; Abdallah AO; Trudel S; Chari A; Libby EN; Chaudhry M; Hultcrantz M; Kortüm KM; Popat R; Sborov D; Hakim S; Lewis E; Gorsh B; Bhushan B; McKeown A; Gupta I; Opalinska J; Richardson PG; Lonial S
Cancer; 2023 Dec; 129(23):3746-3760. PubMed ID: 37622738
[TBL] [Abstract][Full Text] [Related]
10. Belantamab Mafodotin: From Clinical Trials Data to Real-Life Experiences.
Morè S; Offidani M; Corvatta L; Petrucci MT; Fazio F
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296910
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics, and efficacy of belantamab mafodotin monotherapy in Japanese patients with relapsed or refractory multiple myeloma: DREAMM-11.
Iida S; Sunami K; Mishima Y; Fujii T; Kato H; Terao T; Matsuzawa Y; Matsubara M; Crossman T; Kremer BE; Gupta I
Int J Hematol; 2023 Nov; 118(5):596-608. PubMed ID: 37668832
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported experiences during and following treatment with belantamab mafodotin for relapsed/refractory multiple myeloma in the DREAMM-2 study.
Cardellino A; Correll JR; Martin M; Gorsh B; Sapra S; Popat R
Front Oncol; 2023; 13():1274659. PubMed ID: 38144529
[TBL] [Abstract][Full Text] [Related]
13. Belantamab Mafodotin: First Approval.
Markham A
Drugs; 2020 Oct; 80(15):1607-1613. PubMed ID: 32936437
[TBL] [Abstract][Full Text] [Related]
14. Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over.
Condorelli A; Garibaldi B; Gagliano C; Romano A; Del Fabro V; Parrinello NL; Longo A; Cosentino S; Di Raimondo F; Conticello C
Acta Haematol; 2021 Nov; ():. PubMed ID: 34839282
[TBL] [Abstract][Full Text] [Related]
15. Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma.
Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Roussou M; Eleutherakis-Papaiakovou E; Spiliopoulou V; Kastritis E; Terpos E; Dimopoulos MA; Gavriatopoulou M
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511588
[TBL] [Abstract][Full Text] [Related]
16. Belantamab mafodotin for relapsed or refractory multiple myeloma.
Gil-Sierra MD; Briceño-Casado MDP
J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
[No Abstract] [Full Text] [Related]
17. FDA Approval Summary: Belantamab Mafodotin for Patients with Relapsed or Refractory Multiple Myeloma.
Baines AC; Ershler R; Kanapuru B; Xu Q; Shen G; Li L; Ma L; Okusanya OO; Simpson NE; Nguyen W; Theoret MR; Pazdur R; Gormley NJ
Clin Cancer Res; 2022 Nov; 28(21):4629-4633. PubMed ID: 35736811
[TBL] [Abstract][Full Text] [Related]
18. Real-world experience with belantamab mafodotin therapy for relapsed/refractory multiple myeloma: A multicentre retrospective study.
Shragai T; Magen H; Lavi N; Gatt M; Trestman S; Zektser M; Ganzel C; Jarchowsky O; Berger T; Tadmor T; Leiba M; Hertzog-Tzarfaty K; Horowitz N; Shapira M; Varssano D; Berger Y; Frenkel S; Krauthammer M; Avivi I; Luttwak E; Cohen YC;
Br J Haematol; 2023 Jan; 200(1):45-53. PubMed ID: 36205375
[TBL] [Abstract][Full Text] [Related]
19. Belantamab Mafodotin-blmf: A Novel Antibody-Drug Conjugate for Treatment of Patients With Relapsed/Refractory Multiple Myeloma.
Ketchum EB; Clarke A; Clemmons AB
J Adv Pract Oncol; 2022 Jan; 13(1):77-85. PubMed ID: 35173991
[TBL] [Abstract][Full Text] [Related]
20. How I treat relapsed and/or refractory multiple myeloma.
Lee HC; Cerchione C
Hematol Rep; 2020 Sep; 12(Suppl 1):8955. PubMed ID: 33042504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]